Recently, we have found that ErbB2 and nucleolin physically interact in cells, and that this interaction leads to activation of ErbB2 and its downstream signaling, which culminates in increased cell growth and tumorigenicity, and in increased disease and mortality risk in breast cancer patients6,20,33. Here, NUCLEOLIN is linked to breast cancer.